We are analyzing https://link.springer.com/article/10.1007/s13300-017-0232-0.

Title:
Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials | Diabetes Therapy
Description:
The objective of this study was to evaluate the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on serum magnesium in hypomagnesemic patients with type 2 diabetes. This post hoc analysis was based on pooled data from four placebo-controlled studies of canagliflozin (N = 2313). The proportion of patients with baseline serum magnesium <0.74 mmol/L who achieved serum magnesium ≥0.74 mmol/L at week 26 was evaluated. At week 26, canagliflozin 100 and 300 mg increased serum magnesium versus placebo in patients with baseline serum magnesium <0.74 mmol/L (17.0% and 19.0% vs 3.9%) and ≥0.74 mmol/L (4.9% and 7.0% vs −1.4%). More patients with baseline serum magnesium <0.74 mmol/L had serum magnesium ≥0.74 mmol/L at week 26 with canagliflozin 100 and 300 mg versus placebo (74.1% and 80.6% vs 28.8%). Canagliflozin was associated with normalization of serum magnesium in hypomagnesemic patients with type 2 diabetes, potentially leading to improved cardiometabolic outcomes. Clinical trial registration: ClinicalTrials.gov Identifiers, NCT01081834, NCT01106677, NCT01106625, NCT01106690.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

magnesium, serum, patients, canagliflozin, diabetes, mmoll, article, type, pubmed, baseline, google, scholar, analysis, data, cas, disease, week, placebo, levels, study, risk, janssen, research, effects, hypomagnesemic, hypomagnesemia, cardiovascular, treatment, llc, glucose, development, trials, cotransporter, studies, versus, nct, sodium, inhibitor, results, increased, normal, kidney, metaanalysis, increase, hypermagnesemia, central, randomized, access, manuscript, gilbert,

Topics {✒️}

article download pdf end-stage renal disease improves model-based indices large-scale outcomes trials mehul desai contributed separate meta-analysis demonstrated privacy choices/manage cookies dose-response meta-analysis janssen scientific affairs yale jf article processing charges distal convoluted tubule increased insulin resistance improved cardiometabolic outcomes canada research chair medical writing support full-time employee increased magnesium levels normalized magnesium levels 76th scientific sessions received research funding standard laboratory assessments mehul desai view enhanced content rapid disease progression coronary artery disease dietary magnesium intake beta cell function ischemic heart disease insulin sensitivity bone mineral density chronic kidney disease incident kidney disease sudden cardiac death diabetes obes metab low serum magnesium poor intestinal absorption future cardiovascular events adverse cardiovascular outcomes severe renal impairment biochim biophys acta named authors meet 52nd annual meeting advisory board membership creative commons license independent risk factor anti-ischemic effects serum magnesium levels congestive heart disease increase magnesium levels

Questions {❓}

Hypomagnesemia in type 2 diabetes: a vicious circle?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials
         description:The objective of this study was to evaluate the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on serum magnesium in hypomagnesemic patients with type 2 diabetes. This post hoc analysis was based on pooled data from four placebo-controlled studies of canagliflozin (N = 2313). The proportion of patients with baseline serum magnesium <0.74 mmol/L who achieved serum magnesium ≥0.74 mmol/L at week 26 was evaluated. At week 26, canagliflozin 100 and 300 mg increased serum magnesium versus placebo in patients with baseline serum magnesium <0.74 mmol/L (17.0% and 19.0% vs 3.9%) and ≥0.74 mmol/L (4.9% and 7.0% vs −1.4%). More patients with baseline serum magnesium <0.74 mmol/L had serum magnesium ≥0.74 mmol/L at week 26 with canagliflozin 100 and 300 mg versus placebo (74.1% and 80.6% vs 28.8%). Canagliflozin was associated with normalization of serum magnesium in hypomagnesemic patients with type 2 diabetes, potentially leading to improved cardiometabolic outcomes. Clinical trial registration: ClinicalTrials.gov Identifiers, NCT01081834, NCT01106677, NCT01106625, NCT01106690.
         datePublished:2017-02-14T00:00:00Z
         dateModified:2017-02-14T00:00:00Z
         pageStart:451
         pageEnd:458
         license:https://creativecommons.org/licenses/by/4.0
         sameAs:https://doi.org/10.1007/s13300-017-0232-0
         keywords:
            Canagliflozin
            Cardiometabolic
            Cardiovascular disease
            Magnesium
            Sodium glucose co-transporter
            Type 2 diabetes
            Internal Medicine
            Diabetes
            Cardiology
            Endocrinology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13300-017-0232-0/MediaObjects/13300_2017_232_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13300-017-0232-0/MediaObjects/13300_2017_232_Fig2_HTML.gif
         isPartOf:
            name:Diabetes Therapy
            issn:
               1869-6961
               1869-6953
            volumeNumber:8
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Healthcare
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Richard E. Gilbert
               affiliation:
                     name:St. Michael’s Hospital, University of Toronto
                     address:
                        name:St. Michael’s Hospital, University of Toronto, Toronto, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Christian Mende
               affiliation:
                     name:University of California, San Diego
                     address:
                        name:University of California, San Diego, La Jolla, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ujjwala Vijapurkar
               affiliation:
                     name:Janssen Research & Development, LLC
                     address:
                        name:Janssen Research & Development, LLC, Raritan, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sue Sha
               affiliation:
                     name:Janssen Research & Development, LLC
                     address:
                        name:Janssen Research & Development, LLC, Raritan, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael J. Davies
               affiliation:
                     name:Janssen Scientific Affairs, LLC
                     address:
                        name:Janssen Scientific Affairs, LLC, Titusville, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Mehul Desai
               affiliation:
                     name:Janssen Research & Development, LLC
                     address:
                        name:Janssen Research & Development, LLC, Raritan, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials
      description:The objective of this study was to evaluate the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on serum magnesium in hypomagnesemic patients with type 2 diabetes. This post hoc analysis was based on pooled data from four placebo-controlled studies of canagliflozin (N = 2313). The proportion of patients with baseline serum magnesium <0.74 mmol/L who achieved serum magnesium ≥0.74 mmol/L at week 26 was evaluated. At week 26, canagliflozin 100 and 300 mg increased serum magnesium versus placebo in patients with baseline serum magnesium <0.74 mmol/L (17.0% and 19.0% vs 3.9%) and ≥0.74 mmol/L (4.9% and 7.0% vs −1.4%). More patients with baseline serum magnesium <0.74 mmol/L had serum magnesium ≥0.74 mmol/L at week 26 with canagliflozin 100 and 300 mg versus placebo (74.1% and 80.6% vs 28.8%). Canagliflozin was associated with normalization of serum magnesium in hypomagnesemic patients with type 2 diabetes, potentially leading to improved cardiometabolic outcomes. Clinical trial registration: ClinicalTrials.gov Identifiers, NCT01081834, NCT01106677, NCT01106625, NCT01106690.
      datePublished:2017-02-14T00:00:00Z
      dateModified:2017-02-14T00:00:00Z
      pageStart:451
      pageEnd:458
      license:https://creativecommons.org/licenses/by/4.0
      sameAs:https://doi.org/10.1007/s13300-017-0232-0
      keywords:
         Canagliflozin
         Cardiometabolic
         Cardiovascular disease
         Magnesium
         Sodium glucose co-transporter
         Type 2 diabetes
         Internal Medicine
         Diabetes
         Cardiology
         Endocrinology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13300-017-0232-0/MediaObjects/13300_2017_232_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs13300-017-0232-0/MediaObjects/13300_2017_232_Fig2_HTML.gif
      isPartOf:
         name:Diabetes Therapy
         issn:
            1869-6961
            1869-6953
         volumeNumber:8
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Healthcare
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Richard E. Gilbert
            affiliation:
                  name:St. Michael’s Hospital, University of Toronto
                  address:
                     name:St. Michael’s Hospital, University of Toronto, Toronto, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Christian Mende
            affiliation:
                  name:University of California, San Diego
                  address:
                     name:University of California, San Diego, La Jolla, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ujjwala Vijapurkar
            affiliation:
                  name:Janssen Research & Development, LLC
                  address:
                     name:Janssen Research & Development, LLC, Raritan, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sue Sha
            affiliation:
                  name:Janssen Research & Development, LLC
                  address:
                     name:Janssen Research & Development, LLC, Raritan, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael J. Davies
            affiliation:
                  name:Janssen Scientific Affairs, LLC
                  address:
                     name:Janssen Scientific Affairs, LLC, Titusville, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Mehul Desai
            affiliation:
                  name:Janssen Research & Development, LLC
                  address:
                     name:Janssen Research & Development, LLC, Raritan, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Diabetes Therapy
      issn:
         1869-6961
         1869-6953
      volumeNumber:8
Organization:
      name:Springer Healthcare
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:St. Michael’s Hospital, University of Toronto
      address:
         name:St. Michael’s Hospital, University of Toronto, Toronto, Canada
         type:PostalAddress
      name:University of California, San Diego
      address:
         name:University of California, San Diego, La Jolla, USA
         type:PostalAddress
      name:Janssen Research & Development, LLC
      address:
         name:Janssen Research & Development, LLC, Raritan, USA
         type:PostalAddress
      name:Janssen Research & Development, LLC
      address:
         name:Janssen Research & Development, LLC, Raritan, USA
         type:PostalAddress
      name:Janssen Scientific Affairs, LLC
      address:
         name:Janssen Scientific Affairs, LLC, Titusville, USA
         type:PostalAddress
      name:Janssen Research & Development, LLC
      address:
         name:Janssen Research & Development, LLC, Raritan, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Richard E. Gilbert
      affiliation:
            name:St. Michael’s Hospital, University of Toronto
            address:
               name:St. Michael’s Hospital, University of Toronto, Toronto, Canada
               type:PostalAddress
            type:Organization
      name:Christian Mende
      affiliation:
            name:University of California, San Diego
            address:
               name:University of California, San Diego, La Jolla, USA
               type:PostalAddress
            type:Organization
      name:Ujjwala Vijapurkar
      affiliation:
            name:Janssen Research & Development, LLC
            address:
               name:Janssen Research & Development, LLC, Raritan, USA
               type:PostalAddress
            type:Organization
      name:Sue Sha
      affiliation:
            name:Janssen Research & Development, LLC
            address:
               name:Janssen Research & Development, LLC, Raritan, USA
               type:PostalAddress
            type:Organization
      name:Michael J. Davies
      affiliation:
            name:Janssen Scientific Affairs, LLC
            address:
               name:Janssen Scientific Affairs, LLC, Titusville, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Mehul Desai
      affiliation:
            name:Janssen Research & Development, LLC
            address:
               name:Janssen Research & Development, LLC, Raritan, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:St. Michael’s Hospital, University of Toronto, Toronto, Canada
      name:University of California, San Diego, La Jolla, USA
      name:Janssen Research & Development, LLC, Raritan, USA
      name:Janssen Research & Development, LLC, Raritan, USA
      name:Janssen Scientific Affairs, LLC, Titusville, USA
      name:Janssen Research & Development, LLC, Raritan, USA

External Links {🔗}(115)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js
Slick

CDN Services {📦}

Crossref

4.74s.

LINK . SPRINGER . COM {}